emapalumab
Sobi acquire Novimmune in deal worth more than £400 million
June 13, 2019Business Services, Research and Development R&D, emapalumab, immuno-oncology, immunology, pharma
Swedish rare disease specialist Sobi has agreed to buy Swiss firm Novimmune ion a deal worth more than £400 million. …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
